Related Experiment Video
Updated: Jan 4, 2026

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
Published on: January 24, 2025
Balancing benefits and risks in the era of biologics
Giovanni Adami1, Kenneth G Saag2, Roland D Chapurlat3
1Rheumatology Unit, University of Verona, Pz Scuro 10, 37135, Verona, Italy.
Abstract:
Biologics are substances synthetized from biological sources used in the prevention and treatment of several diseases. Rheumatologists have many years of experience with biologics for the treatment of immune-mediated diseases and osteoporosis. Randomized clinical trials and postmarketing studies have demonstrated that treatment with biologics can result, albeit infrequently, in serious adverse events. To date, several risk mitigation strategies have been identified and implemented. The objective of the present perspective review is to examine the risk mitigation strategies of biologic treatments, with special focus on anti-tumor necrosis factors and denosumab.
More Related Videos
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Bioequivalence studies: Biowaivers
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Bioequivalence: Overview
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

